Monocyte Phenotypic and Functional Differences
NCT02132182 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15
Last updated 2018-06-29
Summary
The purpose of this study is to identify phenotypic (cell surface receptor expression) and functional differences in monocyte populations in humans with osteosarcoma as compared to published historical data on normal human monocyte values.
The biologic similarity between canine and human osteosarcoma makes it a disease model that holds promise for translational research possibilities. The phenotypic and functional differences the investigators expect to find in canine and human monocytes between normal and osteosarcoma subjects in this pilot work will allow us to launch a program of investigations to further their understanding as to what characteristics are associated with improved survival in canine and human osteosarcoma. Such data will represent the foundation upon which the investigators can plan future investigations designed to exploit the potential anti-tumor capabilities of monocytes and macrophages in canine and human osteosarcoma.
Conditions
Interventions
- BIOLOGICAL
-
Blood draw
The patient population for this study will be comprised of individuals who present to clinic with newly diagnosed osteosarcoma with or without infection and without known metastasis to the lung. These patients would have a standard-of-care blood draw. For the study we will be drawing an additional 15-20mL of blood (no additional needle stick).
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
William Eward, MD, DVM · Duke University
Eligibility
- Min Age
- 6 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-10-31
- Primary Completion
- 2017-03-23
- Completion
- 2017-03-23
Countries
- United States
Study Locations
More Related Trials
-
Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
NCT01918241 ·Status: UNKNOWN ·Phase: PHASE2
-
Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma
NCT00932217 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
NCT00111462 ·Status: COMPLETED ·Phase: PHASE2
-
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia
NCT02805205 ·Status: COMPLETED ·Phase: PHASE4
-
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
NCT04174742 ·Status: RECRUITING
-
Surveillance Study of Patients With Newly Diagnosed Osteosarcoma
NCT01194284 ·Status: TERMINATED
-
Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated
NCT02921191 ·Status: COMPLETED
-
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
NCT04554056 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy
NCT00883181 ·Status: COMPLETED
-
Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
NCT04009941 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood
NCT00117442 ·Status: COMPLETED ·Phase: PHASE2
-
Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
NCT00503854 ·Status: COMPLETED
-
A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
NCT01560195 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients
NCT01238562 ·Status: COMPLETED ·Phase: PHASE1
-
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia
NCT02996617 ·Status: UNKNOWN ·Phase: PHASE4
-
Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the Test Injectable Formulation BK0023 vs. Neupogen®
NCT01933971 ·Status: COMPLETED ·Phase: PHASE1
-
Profiling Neutrophil Counts in Patients on Chemotherapy
NCT02806557 ·Status: UNKNOWN
-
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
NCT04662892 ·Status: UNKNOWN
-
Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer
NCT03618810 ·Status: UNKNOWN
-
The Efficacy and Safety of PEG-rhG-CSF(Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy
NCT02944604 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Body Mass on Filgrastim Pharmacokinetics
NCT01719432 ·Status: COMPLETED
-
The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy
NCT02905916 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis
NCT03701841 ·Status: UNKNOWN
-
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
NCT02005458 ·Status: COMPLETED ·Phase: PHASE2
-
Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor
NCT07096479 ·Status: RECRUITING